Xiaobin Yuan

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

David P. Steensma, Martin Wermke, Virginia M. Klimek et al. · Leukemia · 2021 · 169 citations · Full text

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yunpeng Yang, Jianya Zhou, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2019 · 135 citations

Biomarker Analysis, Medicine, Pharmacology +8

Modeling and characterization of dielectric-charging effects in RF MEMS capacitive switches

Xiaobin Yuan, James C. M. Hwang, David Forehand et al. · IEEE MTT-S International Microwave Symposium Digest, 2005. · 2005 · 113 citations

Electrical Engineering, Dielectrics, Engineering +10

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

David P. Steensma, Martin Wermke, Virginia M. Klimek et al. · Blood · 2019 · 88 citations

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Shun Lü, Jianying Zhou, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 63 citations

First-line Therapy, Medicine, Randomised Phase 3 +8